Leerink Partners has recently reduced CureVac BV (CVAC) stock to Market Perform rating, as announced on April 25, 2024, according to Finviz. Earlier, on June 8, 2023, SVB Securities had initiated the ...
CVGBM, an investigational cancer vaccine, induced T-cell responses in patients with MGMT-unmethylated glioblastoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback